Chris Conner
291 episodes listed below
PRESS PLAY
How will AI, CRISPR, CGT and other new technologies impact life science? I'm following my curiosity. Follow along with me. cclifescience.substack.com
Based on 6 episodes we listened to · September 2026
Chris Conner makes the organizational and commercial work surrounding science unusually concrete.
Chris Conner keeps returning to the point where scientific work meets the organizations that have to explain, fund, sell, and sustain it. The interview format gives cc: Life Science Podcast room to connect science communication with concrete business decisions, from responding…
The scientist has to sell now; Chris Conner asks how you get past the wince.
Press play if you want
Short reviews from the PlayNext desk, based on the episodes we processed.
A practical look at how life science sales teams can take some of the busywork off the plate.
Harrison Wade makes a steady case for life science sales teams to rely on systems instead of pure hustle. He traces the older pattern of founder led selling, early reps, and a lot of manual work that drags technical people away from customers, then moves into how AI and…
A sharp look at marketing noise, brand pushback, and the value of hiring well.
Chris Conner and Abdul Rastegar turn a familiar marketing headache into something concrete: plenty of opinions, not much signal, and the work of deciding which feedback deserves a response.
Biotech sales, lead gen, and LinkedIn discipline shape a practical, useful episode.
TLDR biotech follows a path from a LinkedIn news roundup into a newsletter and then a service business, with a side thread about learning biotech sales on the fly.
Trust is framed as a founder problem, not a slogan.
It treats founder trust as a practical choice rather than a slogan, connecting it to origin, motive, and the reason a company exists in the first place.
A cold-chain conversation about continuous tracking, customer problems, and why innovation still has to make business sense.
The piece follows a cold storage and cold shipping system, with Faizan Ahmed, founder and CEO of Invencify, laying out how the tracking stack functions and why it matters.
A scientist-to-sales story that treats listening as the real competitive advantage.
Heather Javier presents the shift from scientist to sales as a lesson in listening, context, and restraint. She moves from biology at San Francisco State to Genentech's translational oncology work, including the exhausting mouse-house grind, and uses that path to show why…
A practical look at selling science when the market has no category yet.
Chris Conner talks with Brian Jamison and Chris Morrison about a basic problem in disruptive tech: how to sell something when there is no familiar category to point to.
Culture work here feels practical, human, and less abstract than it first sounds.
Michaela Auld treats organizational culture as something that reaches past the office, and Chris Conner keeps the discussion tied to day to day work.
Mushroom culture from soil to society.
Clear neuroscience for curious minds.
Plant papers, jokes, and useful uncertainty.
Weed science, from genomes to paddocks.
Biomedical careers, described from the inside.
Human stakes behind biomedical progress.
Elizabeth Schaub, CEO of High Touch Group and author of The Giant's Ladder, argues that life science companies should make scientists visible as cultural icons instead of leaving them inside journals.
Tiffany's badge said none.
Chris Burnett, president of All Good Marketing and adjunct professor at Kent State University, argues that Ontario life sciences already have the education, infrastructure, and talent to compete globally.
Chris Conner talks with Anis Fahandij-Sadi about the path from science into sales.
Chris Conner interviews Tino Chow, founder and CEO of Giant Shoulders, about how medtech and life science founders build trust before they have credibility.
Chris Conner talks with Joachim Ikut, founder of LaBiotech and voice behind The Science Marketer, about how a 2012 biotech blog became a European media company.
Chris Conner talks with Meg Schlabs about branding as a careful, collaborative process.
Gudrun Stengel, CEO and co-founder of Alita Biosciences, explains how RNA modifications affect alternative splicing, translation initiation, RNA trafficking, and messenger RNA half-life.
Chris Conner interviews Harrison Wade, co-founder of Succession Bio, about the shift from old-school life science sales to a more automated model.
Faizan Ahmed talks about Invencify's cold storage and cold shipping unit.
Abdul Rastegar discusses cutting through marketing BS, focusing on outdated processes, pricing transparency, and the importance of thought leadership.
Deb Nathan introduces conflict navigation as a paradigm shift from resolution, emphasizing relational resilience in team dynamics.
Chris interviews Petrina Kamenek from Insilico Medicine about using AI to improve drug development success rates, covering topics like target identification, molecule design, clinical trial patient stratification, and applications in herbicide development.
The episode opens with a question about what first pulled the guest toward science.
Carter Mitchell, CSO of Kemp Proteins, says the company has spent about 30 years building protein solutions and now combines protein engineering, machine learning, artificial intelligence, and quantitative analytics.
Elizabeth Schaub says Fierce reported more than $1.8 billion in NIH cuts and 684 grant programs wiped out, which she links to a slow damage cycle in basic research, preclinical work, and future health care innovation.
Chris Conner speaks with Nick Clare, co-founder of Succession and co-host of the SalesDNA podcast, about how a scientist ended up in sales after being made redundant while his wife was 14 weeks pregnant with their third child.
Heather Javier, a genomic sales specialist at Roche, describes moving from a biology degree at San Francisco State and lab roles at Genentech, UCSF Diabetes Center, and City of Hope into sales after a year of networking on LinkedIn.
Max Gilbert of T-Ferret Consulting works with startup founders selling hardware, software, and services into biotech, healthcare, and life sciences, especially people with engineering, science, or medical backgrounds who have never done sales.
Julian Willard, a board advisor and strategist for biopharma leaders, argues that small molecules are undervalued even though FDA data from 2009 to 2023 shows they made up 73% of new drug approvals.
Jeremy Elser, head of science operations at Talenteer and CEO of Ship of Theseus, connects anti-aging research to a philosophical ship-paradox and says his goal is to keep the body rebuilding itself.
Chris Morrison of Via Veris and Brian Jamison of Diagnostic Biochips talk about selling a disruptive neural-probe platform that measures action potentials, or the sequence and timing of “ones and zeros” from neurons.
Norman Wen, CEO of Soteria, describes the Chorus bed, a self-positioning sleep system built around SUDEP prevention and AI-driven posture detection.
Chris talks with Jan Juveno, director of product at N6 Tech, about Icon PCR and why the company thinks a 30-year-old step in genomics still needs redesigning.
Michaela Auld, founder and chief culture officer of the WorkWell Studio, argues on Life Science Marketing Radio that organizational culture can affect society beyond the walls of a company or agency.
Oliver Pierce opens with Apista Life Sciences' life-science brief.
Chris Conner speaks with Isabel Verniers.
Chris Conner frames this ALFC double feature around two companies showing practical ways to make lateral flow testing easier to use: Otomo Diagnostics and EaseBio.
Jin Kim, CEO and founder of Miracle, says his company integrates clinical trial systems into one real-time dashboard and has helped some phase two and phase three studies finish 3–4 months ahead of schedule.